Cox regression analysis of specific prognostic factors
| . | EFS from study entry . | RR from end of course 1 . | ||||||
|---|---|---|---|---|---|---|---|---|
| No. . | HR . | 95% CI . | P . | No. . | HR . | 95% CI . | P . | |
| Univariate Cox analyses, stratified by study | ||||||||
| CEBPA mutation, vs no mutation | 38 | 0.47 | 0.25-0.87 | .015 | 32 | 0.26 | 0.08-0.80 | .019 |
| CBF AML, vs normal/other cyto | 201 | 0.47 | 0.35-0.63 | < .001 | 187 | 0.46 | 0.32-0.67 | < .001 |
| High risk by cyto, vs normal/other cyto | 44 | 2.13 | 1.44-3.13 | < .001 | 26 | 2.89 | 1.59-5.24 | < .001 |
| High risk FLT3/ITD, vs low risk | 76 | 1.90 | 1.42-2.54 | < .001 | 52 | 2.55 | 1.73-3.78 | < .001 |
| WBC, 100 000 or more vs less than 100 000 | 212 | 1.31 | 1.07-1.61 | .010 | 153 | 1.20 | 0.89-1.61 | .237 |
| Multivariate Cox analyses, stratified by study | ||||||||
| CEBPA mutation, vs no mutation | 21 | 0.36 | 0.15-0.87 | .024 | 20 | 0.24 | 0.06-0.98 | .047 |
| CBF AML, vs normal/other cyto | 146 | 0.48 | 0.35-0.68 | < .001 | 136 | 0.49 | 0.31-0.76 | .001 |
| High risk by cyto, vs normal/other cyto | 22 | 2.18 | 1.27-3.74 | .005 | 13 | 3.24 | 1.37-7.68 | .008 |
| High risk FLT3/ITD, vs low risk | 35 | 1.87 | 1.23-2.84 | .003 | 22 | 2.66 | 1.52-4.67 | < .001 |
| WBC, 100 000 or more vs less than 100 000 | 88 | 1.34 | 0.97-1.86 | .079 | 63 | 1.23 | 0.77-1.96 | .390 |
| . | EFS from study entry . | RR from end of course 1 . | ||||||
|---|---|---|---|---|---|---|---|---|
| No. . | HR . | 95% CI . | P . | No. . | HR . | 95% CI . | P . | |
| Univariate Cox analyses, stratified by study | ||||||||
| CEBPA mutation, vs no mutation | 38 | 0.47 | 0.25-0.87 | .015 | 32 | 0.26 | 0.08-0.80 | .019 |
| CBF AML, vs normal/other cyto | 201 | 0.47 | 0.35-0.63 | < .001 | 187 | 0.46 | 0.32-0.67 | < .001 |
| High risk by cyto, vs normal/other cyto | 44 | 2.13 | 1.44-3.13 | < .001 | 26 | 2.89 | 1.59-5.24 | < .001 |
| High risk FLT3/ITD, vs low risk | 76 | 1.90 | 1.42-2.54 | < .001 | 52 | 2.55 | 1.73-3.78 | < .001 |
| WBC, 100 000 or more vs less than 100 000 | 212 | 1.31 | 1.07-1.61 | .010 | 153 | 1.20 | 0.89-1.61 | .237 |
| Multivariate Cox analyses, stratified by study | ||||||||
| CEBPA mutation, vs no mutation | 21 | 0.36 | 0.15-0.87 | .024 | 20 | 0.24 | 0.06-0.98 | .047 |
| CBF AML, vs normal/other cyto | 146 | 0.48 | 0.35-0.68 | < .001 | 136 | 0.49 | 0.31-0.76 | .001 |
| High risk by cyto, vs normal/other cyto | 22 | 2.18 | 1.27-3.74 | .005 | 13 | 3.24 | 1.37-7.68 | .008 |
| High risk FLT3/ITD, vs low risk | 35 | 1.87 | 1.23-2.84 | .003 | 22 | 2.66 | 1.52-4.67 | < .001 |
| WBC, 100 000 or more vs less than 100 000 | 88 | 1.34 | 0.97-1.86 | .079 | 63 | 1.23 | 0.77-1.96 | .390 |